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Abstract 
Introduction: Experimental and clinical data accumulated over the past decade indicate a number of pleiotropic effects 
that are inherent in incretinomimetics. These effects are due to the wide distribution of GLP-1 receptors (GLP-1R) in many 
organs and tissues. 
Objective: Study of hepatoprotective activity of exenatide and vildagliptin on the liver ischemia/reperfusion model, taking 
into account biochemical and morphological parameters. 
Methods: Ischemia-reperfusion injury of the liver was reproduced by 15-minute clamping of the rat liver-duodenal 
ligament analogue with subsequent restoration of blood flow and removal of the animal from the experiment on the 3rd 
day. Exenatide at a dose of 10 μg/kg was administered subcutaneously, vildagliptin orally at a dose of 0.2 mg/kg 2 hours 
before the experiment. 
Results: Exenatide (10 μg/kg) and vildagliptin (0.2 mg/kg) reduced hepatocellular ischemia/reperfusion injury, which 
resulted in preventing the increased activity of AST and ALT transaminases, reducing necrosis areas by 1.9 times 
(compared with the ischemia/reperfusion group), reducing the infiltration of stromal and parenchymal elements of the liver, 
reducing edema. 
Conclusion: The hepatoprotective effects of exenatide and vildagliptin identify them as potentially effective drugs for 
correcting ischemic/reperfusion injury of the liver. 
Keywords: Ischemia-reperfusion, Liver, Incretinomimetics, Exenatide, Vildagliptin, Hepatoprotection. 
 
Introduction 
Currently, a wide range of methods for the 
prevention and correction of disorders arising from 
ischemia/reperfusion syndrome of the liver has been 
developed. One of these approaches is ischemic 
preconditioning, the essence of which is short-term 
ischemic-reperfusion effect by applying/removing the 
clamp on afferent liver vessels before or after the 
main ischemia episode [1], as a result, there is an 
improvement in microcirculatory and metabolic 
processes, the activity of the LPO decreases, 
decreases production of pro-inflammatory cytokines 
[2-4, 64]. Despite the promising results of 
experimental studies, ischemic preconditioning 
showed no effect in clinical trials [5]. From a clinical 
point of view, preconditioning with pharmacological 
agents seems preferable. For this purpose, various 
drugs have been studied: antioxidants (glutathione, α-
tocopherol, acetylcysteine, ascorbic acid, α-lipoic 
acid), as well as antioxidant gene therapy, cytokine 
receptor antagonists and inhibitors of the complement 
system, apoptosis inhibitors (Z-DEVD-FMK - 
inhibitor 3 and 7 of caspases), hormones and 
hormone-like substances (erythropoietin, melatonin, 
methylprednisolone), vasodilators (precursors and NO 
donators, prostacyclin analogues), 
immunosuppressants (cyclosporine), as well as 
enzyme inhibitors - cyclooxygenase-2, x antioxidase, 
NADH oxidase [6-13]. At the same time, none of the 
proposed methods and their combinations provide 
guaranteed protection against ischemic-reperfusion 
injury of the liver with potential development in the 
postoperative period of its dysfunction [14], and 
therefore the search and selection of innovative and 
promising compounds and preparations of this 
direction of action continues. 
Preclinical studies at the cellular, molecular [15-
17], organ [18-21, 63], systemic and organism levels 
[22-28, 61], including specific activity [29-35, 58-60] 
and toxicological studies [36, 62] in combination with 
bioequivalence studies [37], therapeutic equivalence 
and effectiveness are an integral part of the research 
of innovative drugs. 
Experimental and clinical data accumulated over 
the past decade indicate a number of pleiotropic 
effects that are inherent in incretinomimetics, which 
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expand their therapeutic potential. In this regard, the 
study of the exenatide and omindagliptin 
increstinomimetics as agents of pharmacological 
preconditioning with the aim of possible prevention 
and correction of the effects of ischemic-reperfusion 
injury of the liver is of particular interest. 
Objectives of the study: study of hepatoprotective 
activity of exenatide and vildagliptin in liver 
ischemia/reperfusion, taking into account biochemical 
and morphological parameters and studying the 
mechanism of their action. 
Materials and Methods 
An experimental study was conducted on 60 male 
Wistar rats weighing 250-300 g. 
Ischemic reperfusion injury of the liver was 
reproduced by 15-minute clamping of the rat liver-
duodenal ligament analogue with subsequent 
restoration of blood flow and removal of the animal 
from the experiment on the 3rd day, this ischemia 
dosing regimen was chosen as one of the most 
common in the study of supraliminal ischemic 
stimulus [10] (Figure 1). 
 
Figure-1: Isolation of the hepatic-duodenal rat 
ligament followed by modeling of 
ischemia/reperfusion 
Exenatide at a dose of 10 μg/kg was administered 
subcutaneously, vildagliptin orally at a dose of 0.2 
mg/kg 2 hours before the experiment. Ademethionine 
was chosen as a reference drug, which was used at a 
dosage of 400 mg/kg intraperitoneally 30 minutes 
before an episode of ischemia. 
Glibenclamide, the K+-ATP-channels blocker, was 
administered at a dose of 5 mg/kg, 30 minutes before 
the introduction of the pharmacological agent. 
Blood samples were taken from all groups of 
animals in order to determine the biochemical 
parameters of AST and ALT, immediately before 
euthanasia (after 3 days of the experiment), and liver 
sites for morphological studies. To assess the severity 
of hepatocellular damage, the activity of aspartate 
aminotransferase (AST) and alanine aminotransferase 
(ALT) was determined by a kinetic photocolorimetric 
method on a Vitalab Flexor E (Netherlands) 
automated biochemical analyzer using Biocon and 
Human reagents (Germany). For the histological 
examination of the liver, areas of 1.0x1.0x0.5 cm were 
taken with subsequent preparation of histological 
microscopic preparations and their staining with 
hematoxylin and eosin, according to Van Gieson, Mac 
Manus and Pappenheim. The study of 
micropreparations, photoprotocoling and 
morphometry was performed on a Leica DM4000B 
microscope with a video recording and image 
processing system. The obtained experimental data 
were processed by methods of variation statistics [38] 
using software. Before starting the procedures of 
statistical processing, data arrays were tested for 
normal distribution using the W Shapiro-Wilk 
criterion. Given the non-normal distribution pattern, 
the data were presented as medians (Me) and quartiles 
(p0.25/p0.75). In connection with the design features 
of the study, the non-parametric U-criterion Mann-
Whitney (for independent groups) was used to 
identify statistical differences between groups. 
Differences in which the level of the confidence 
interval (p) was more than 95% (p<0.05) were 
considered significant. 
Results and Discussion 
In order to assess the effectiveness of using 
exenatide and vildagliptin as a cytoprotectant in 
conditions of liver ischemia/reperfusion, the activity 
of classical markers of cytolysis of hepatocytes in 
blood plasma was determined (Table 1). The data 
obtained indicate the development and increase of 
cytolytic syndrome in animals in groups with 
ischemia. Thus, in rats subjected to a 15-minute 
shutdown of the liver from the systemic circulation, 
there was an increase in the release of hepatocyte 
enzymes into the blood with an increase in ALT 
activity by 2.8 times and to a lesser extent AST - 2.0 
times in comparison with the group of false-operated 
animals (Table 1). 
Table-1: The protective effect of exenatide and 
vildagliptin on transaminases on the background of 
glibenclamide during liver ischemia/reperfusion 
(M±m; n=10) 
Animal Group AST (unit/l) ALT(unit/l) 
Intact 110.3±13.81 61.4±19.91 
Sham operated 115.2±12.3** 64.8±27.3** 
Control 234.1±23.2*1 183.1±16.81* 
Exenatide 10 mcg/kg 130.2±15.9** 107.1±11.7** 
Vildagliptin 0.2 mg/kg 123.6±18.5** 89.8±27.3** 
Ademethionine 400mg/kg 170.2±6.7* 149.7±5.1* 
Glibenclamide 5 mg/kg + exenatide 
10mg/kg 229.7±20.5
*1 171.4±18.2*1 
Glibenclamide 5 mg/kg + vildagliptin 0.2 
mg/kg 232.4±19.7
*1 174.5±22.4*1 
Note: * - p> 0.05 compared with a group of intact 
animals; 1– p <0.05 compared with the group of the 
sham-operated; ** - p <0.05 compared with the 
control group. 
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The activity of AST and ALT with a 15-minute 
shutdown of the liver from the systemic circulation on 
the background of the administration of exenatide to 
animals 10 µg/kg and vildagliptin 0.2 mg/kg differed 
from that of rats who did not receive drugs. Thus, with 
vascular isolation of the liver on the background of 
exenatide 10 μg/kg and vildagliptin 0.2 mg/kg, AST 
and ALT were significantly lower than the control 
group and amounted to 130.2±15.9 u/ l and 107.1 ± 11 
for exenatide. 7 units/l for vildagliptin: 123.6±18.5 
units/ l and 89.8 ± 27.3 units/ l, respectively. Thus, the 
use of incretinomimetics for 3 days to correct liver 
ischemia/reperfusion made it possible to reduce the 
development of hepatocyte cytolysis. 
The comparison drug ademethionin 400 mg/kg 
AST and ALT was lower than in the control group, 
but higher than in the group with exenatide 10 μg/kg 
and vildagliptin 0.2 mg/kg (Table 1). 
In order to determine the mechanism for the 
implementation of the protective action of exenatide 
and vildagliptin, 30 minutes before distant ischemic 
preconditioning a blocker of ATP-dependent 
K+channels glibenclamide was used as a 
pharmacological analyzer intraperitoneally at a dose 
of 5 mg/kg.  
Pretreatment with 5 mg/kg glibenclamide resulted 
in an increase in AST and ALT, which is comparable 
with the ischemia/reperfusion group and leveled the 
anti-ischemic effect of incretinomimetics (Table 1). 
A morphological study in the control group 
revealed that significant changes in nuclei 
characterized by vacuolization, chromatin 
fragmentation until complete disappearance, with 
chromatin residues along the periphery of the nucleus. 
In hepatocytes, there are few unchanged nucleoli. 
Cytoplasm had significant granular and adipose 
degeneration.  
There is significant edema, characterized by a 
sharp expansion of the Disse space. Foci of necrosis 
with regenerative hypertrophic hepatocytes along the 
periphery and foci of lymphocytic and thick leukocyte 
infiltration are expressed.  
Necrosis is localized subcapsular and around the 
hepatic tracts. Glycogen in hepatocytes is diffuse, 
exists not in all cells (Figure 2). 
On average, the area of necrosis in the control 
group was 0.217±0.014 mm2 (Table 2). 
  
Figure-2: Morphological changes in the liver during 
ischemia/reperfusion. 
A) The intact group - structure of the liver tissue is 
preserved, the lobules and portal tracts are clear. 
B) The group of ischemia/reperfusion - the structure is 
broken, visible foci of necrosis, fat: infiltration of 
hepatocytes. Stained with hematoxylin and eosin. 
Microphoto. X 100. 
By simulating ischemia/reperfusion of the liver, 
both studied incretinomimetics contributed to a 
reliable correction of hepatocyte functioning. The 
necrosis area when used with exenatide and 
vildagliptin decreased by 1.7 and 1.9 times, 
respectively, and averaged to 0.126±0.012 and 
0.118±0.008 mm2 (Table 2). 
Table-2: The protective effect of exenatide and 
vildagliptin on the necrosis area on the background 
of glibenclamide during liver ischemia/reperfusion 
(M±m; n=10) 
№ Animal Groups Necrosis area, 
mm2 
1. Sham operated - 
2. Ischemia/reperfusion (control) 0.217±0.014 
3. Exenatide 10 mcg/kg 0.126±0.012* 
4. Vildagliptin 0.2 mg/kg 0.118±0.008
* 
5. Ademethionine 400mg/kg 0.189±0.011
* 
6. Glibenclamide 5 mg/kg + 
exenatide 10µg/kg 
0.210±0.017 
7. Glibenclamide 5 mg/kg + 
vildagliptin 0.2 mg/kg 
0.213±0.012 
Note: * p≤0.05 when compared with the ischemia / 
reperfusion group. 
Morphological changes were reduced to 
minimizing the swelling of Disse spaces, reducing 
infiltrative changes (Figure 3). 
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Figure-3: The effect of exenatide 10 µg/kg and 
vildagliptin 0.2 mg/kg on ischemia/reperfusion of 
the liver. 
A) The group with the use of exenatide 10 μg/kg: 
the structure of the liver is preserved, isolated foci of 
necrosis. 
B) Group using vildagliptin 0.2 mg/kg: 
micronecrosis, hepatocyte fatty infiltration. Stained 
with hematoxylin and eosin. Microphoto. X 100. 
The comparison drug ademethionine at a dose of 
400 mg/kg reduced the area of necrosis to a much 
lesser extent than incretinomimetics - 0.189±0.011 
mm2 (Table 2).  
Using exenatide 10 µg/kg and vildagliptin 0.2 
mg/kg on the background of the ATP blocker K+ 
channels of glibenclamide 5 mg/kg showed a decrease 
of necrosis areas in their effectiveness, and 
approached the control group in size (Table 2). 
The data obtained during the work indicate a 
powerful hepatoprotective effect of exenatide 10 
μg/kg and vildagliptin 0.2 mg/kg, which is 
accompanied by a decrease in the severity of 
hepatocellular damage in ischemic/reperfusion 
injuries of the liver, manifested by a decrease in 
transaminase activity and a decrease in areas of 
necrosis. 
The proposed mechanism of hepatoprotective 
action is realized through the activation of 
mitochondrial ATP-dependent K+ channels, as 
evidenced by the complete abolition of the protective 
action against the introduction of the ATP blocker K+ 
channels glibenclamide (5 mg/kg).  
Due to ischemia and subsequent liver reperfusion, 
a cascade of metabolic, morphological and 
immunological changes in the liver is launched, which 
can potentially lead to the development of liver failure 
in the early postoperative period, which is especially 
dangerous for patients with chronic hepatitis and liver 
cirrhosis. In addition, there is evidence of accelerated 
growth of colorectal micrometastases with prolonged 
ischemic liver damage under vascular occlusion [39]. 
In addition, ischemia-reperfusion of the graft of 
varying severity is present at each liver transplant and 
contributes significantly to its early postoperative 
dysfunction. In this regard, it is relevant to search and 
use drugs that minimize the effects of 
ischemic/reperfusion injury of the liver. 
Intensive studies of the mechanisms of the 
incretinomimetics anti-ischemic action have provided 
significant progress in understanding the 
implementation of the principle of their action [40].  
Normally, GLP-1R is identified in the pancreas, 
intestines, lungs, adipose tissue, muscles, kidneys, 
heart, endothelial, smooth muscle cells (SMC), 
macrophages and monocytes, as well as in neurons 
and glial cells [41-43]. However, GLP-1R-
independent effects of GLP-1 are not excluded, in 
particular, their ability to activate ATP-dependent K+ 
channels [43-47]. In a number of studies, preliminary 
introduction of glibenclamide (an ATP-dependent 
potassium channel blocker) resulted in the 
disappearance of the cardioprotective, endothelial-
protective effect of GLP-1R activation. A number of 
authors suggest that the protective mechanisms of 
action of GLP-1 are mediated including the discovery 
of ATP-dependent K+mitochondria. Their discovery 
is known to be a key element in the phenomenon of 
ischemic preconditioning, which involves several 
intracellular signaling pathways, including RISK 
pathways (Reperfusion injury kinase/RISK/pathway) - 
protein kinase A, phosphoinositol-3-kinase (PI3K), 
protein kinase B and extracellular signal-regulated 
kinases (ERK1/2). Probably, the anti-apoptotic effect 
of GLP-1 is associated with the RISK kinase pathway, 
which protects against reperfusion injury by reducing 
the permeability of the mitochondrial membrane [48-
49]. RISK kinases inhibit the opening of highly 
permeable mitochondrial pores (MPTP), block cell 
overload with calcium ions, which triggers anti-
apoptotic pathways, or blocks the initiation of 
apoptotic factors. 
According to the authors, activation of the GLP-1 
receptor is able to induce preconditioning 
mechanisms. 
GLP-1R agonists and DPP-4 inhibitors can 
increase the expression of the antioxidant enzyme 
hemoxygenase-1 (HO-1), a stress-inducible enzyme, 
which limits the rate of heme degradation and protects 
the cell from oxidative stress. Some researchers 
attribute this to GPP1R-mediated activation of the 
transcription factor Nrf2 
(GPP1R/PKA(PKB)/CREB/Nrf2), regulating gene 
expression of antioxidant enzymes (glutathione-S-
transferase, UDP-glucuronyl transferase, heme 
oxygenase-1, etc.). [50-57] 
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Conclusion 
The data obtained during the research indicate the 
hepatoprotective effect of incretinomimetics, which is 
accompanied by a decrease in the severity of 
hepatocellular damage in ischemic and reperfusion 
injuries of the liver. The effect of the complete 
abolition of the protective action using the 
mitochondrial blocker ATP-dependent K+channels 
glibenclamide, suggests the implementation of the 
protective effect through ATP-dependent potassium 
channels. 
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